JSW
REGN icon

Journey Strategic Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Journey Strategic Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
1,572
+265
+20% +$203K 0.03% 159
2025
Q4 		$1.01M Buy
1,307
+90
+7% +$61.1K 0.03% 179
2025
Q3 		$684K Buy
1,217
+474
+64% +$268K 0.02% 229
2025
Q2 		$390K Buy
743
+167
+29% +$93.2K 0.01% 351
2025
Q1 		$365K Buy
576
+99
+21% +$68.1K 0.01% 290
2024
Q4 		$340K Sell
477
-202
-30% -$170K 0.01% 303
2024
Q3 		$714K Buy
679
+97
+17% +$108K 0.03% 168
2024
Q2 		$612K Buy
582
+226
+63% +$219K 0.03% 142
2024
Q1 		$343K Buy
356
+49
+16% +$46.6K 0.02% 167
2023
Q4 		$270K Buy
+307
New +$253K 0.01% 156
2023
Q2 		– Sell
-334
Closed -$274K – 257
2023
Q1 		$274K Buy
+334
New +$252K 0.03% 170

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Journey Strategic Wealth's REGN Position: Q1 2026 in Review

Journey Strategic Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 20% in Q1 2026, buying an estimated $203K and bringing the position to 1,572 shares worth $1.21M. The position accounts for 0.03% of the portfolio, ranked #159.

Journey Strategic Wealth first reported a position in REGN in Q1 2023 and has held it in 11 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Journey Strategic Wealth held 1,572 shares of Regeneron Pharmaceuticals worth $1.21M as of Q1 2026.
  • Journey Strategic Wealth bought 265 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • Regeneron Pharmaceuticals made up 0.03% of Journey Strategic Wealth's portfolio in Q1 2026, its #159 holding.
  • Journey Strategic Wealth first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.